Quantitative micro-CT-derived biomarkers elucidate age-related lung fibrosis in elder mice.
Animals
Male
Mice, Inbred C57BL
Mice
Bleomycin
/ toxicity
Biomarkers
/ metabolism
X-Ray Microtomography
/ methods
Aging
/ pathology
Idiopathic Pulmonary Fibrosis
/ drug therapy
Disease Models, Animal
Indoles
/ administration & dosage
Age Factors
Pulmonary Fibrosis
/ diagnostic imaging
Lung
/ drug effects
Age
Bleomycin model
IPF
Lung fibrosis
Micro-computed tomography
Nintedanib
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
30 Oct 2024
30 Oct 2024
Historique:
received:
08
07
2024
accepted:
07
10
2024
medline:
31
10
2024
pubmed:
31
10
2024
entrez:
31
10
2024
Statut:
epublish
Résumé
Idiopathic Pulmonary Fibrosis (IPF), prevalently affecting individuals over 60 years of age, has been mainly studied in young mouse models. The limited efficacy of current treatments underscores the need for animal models that better mimic an aged patient population. We addressed this by inducing pulmonary fibrosis in aged mice, using longitudinal micro-CT imaging as primary readout, with special attention to animal welfare. A double bleomycin dose was administered to 18-24 months-old male C57Bl/6j mice to induce pulmonary fibrosis. Bleomycin dosage was reduced to as low as 75% compared to that commonly administered to young (8-12 weeks-old) mice, resulting in long-term lung fibrosis without mortality, complying with animal welfare guidelines. After fibrosis induction, animals received Nintedanib once-daily for two weeks and longitudinally monitored by micro-CT, which provided structural and functional biomarkers, followed by post-mortem histological analysis as terminal endpoint. Compared to young mice, aged animals displayed increased volume, reduced tissue density and function, and marked inflammation. This increased vulnerability imposed a bleomycin dosage reduction to the lowest tested level (2.5 µg/mouse), inducing a milder, yet persistent, fibrosis, while preserving animal welfare. Nintedanib treatment reduced fibrotic lesions and improved pulmonary function. Our data identify a downsized bleomycin treatment that allows to achieve the best trade-off between fibrosis induction and animal welfare, a requirement for antifibrotic drug testing in aged lungs. Nintedanib displayed significant efficacy in this lower-severity disease model, suggesting potential patient stratification strategies. Lung pathology was quantitatively assessed by micro-CT, pointing to the value of longitudinal endpoints in clinical trials.
Sections du résumé
BACKGROUND
BACKGROUND
Idiopathic Pulmonary Fibrosis (IPF), prevalently affecting individuals over 60 years of age, has been mainly studied in young mouse models. The limited efficacy of current treatments underscores the need for animal models that better mimic an aged patient population. We addressed this by inducing pulmonary fibrosis in aged mice, using longitudinal micro-CT imaging as primary readout, with special attention to animal welfare.
METHODS
METHODS
A double bleomycin dose was administered to 18-24 months-old male C57Bl/6j mice to induce pulmonary fibrosis. Bleomycin dosage was reduced to as low as 75% compared to that commonly administered to young (8-12 weeks-old) mice, resulting in long-term lung fibrosis without mortality, complying with animal welfare guidelines. After fibrosis induction, animals received Nintedanib once-daily for two weeks and longitudinally monitored by micro-CT, which provided structural and functional biomarkers, followed by post-mortem histological analysis as terminal endpoint.
RESULTS
RESULTS
Compared to young mice, aged animals displayed increased volume, reduced tissue density and function, and marked inflammation. This increased vulnerability imposed a bleomycin dosage reduction to the lowest tested level (2.5 µg/mouse), inducing a milder, yet persistent, fibrosis, while preserving animal welfare. Nintedanib treatment reduced fibrotic lesions and improved pulmonary function.
CONCLUSIONS
CONCLUSIONS
Our data identify a downsized bleomycin treatment that allows to achieve the best trade-off between fibrosis induction and animal welfare, a requirement for antifibrotic drug testing in aged lungs. Nintedanib displayed significant efficacy in this lower-severity disease model, suggesting potential patient stratification strategies. Lung pathology was quantitatively assessed by micro-CT, pointing to the value of longitudinal endpoints in clinical trials.
Identifiants
pubmed: 39478545
doi: 10.1186/s12931-024-03006-7
pii: 10.1186/s12931-024-03006-7
doi:
Substances chimiques
Bleomycin
11056-06-7
Biomarkers
0
nintedanib
G6HRD2P839
Indoles
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
393Informations de copyright
© 2024. The Author(s).
Références
Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198:e44–68.
doi: 10.1164/rccm.201807-1255ST
pubmed: 30168753
Podolanczuk AJ, Thomson CC, Remy-Jardin M, Richeldi L, Martinez FJ, Kolb M, et al. Idiopathic pulmonary fibrosis: state of the art for 2023. Eur Respir J. 2023;61:2200957.
doi: 10.1183/13993003.00957-2022
pubmed: 36702498
Trachalaki A, Irfan M, Wells AU. Pharmacological management of idiopathic pulmonary fibrosis: current and emerging options. Expert Opin Pharmacother. 2021;22:191–204.
doi: 10.1080/14656566.2020.1822326
pubmed: 32993388
Raghu G, Richeldi L, Fernández Pérez ER, De Salvo MC, Silva RS, Song JW et al. Pamrevlumab for Idiopathic Pulmonary Fibrosis: the ZEPHYRUS-1 Randomized Clinical Trial. JAMA Published Online May 19, 2024.
Maher TM, Ford P, Brown KK, Costabel U, Cottin V, Danoff SK, et al. Ziritaxestat, a novel autotaxin inhibitor, and lung function in idiopathic pulmonary fibrosis: the ISABELA 1 and 2 randomized clinical trials. JAMA. 2023;329:1567–78.
doi: 10.1001/jama.2023.5355
pubmed: 37159034
pmcid: 10170340
Bärnthaler T, Ramachandra AB, Ebanks S, Guerrera N, Sharma L, Dela Cruz CS, et al. Developmental changes in lung function of mice are independent of sex as a biological variable. Am J Physiol Lung Cell Mol Physiol. 2024;326:L627–37.
doi: 10.1152/ajplung.00120.2023
pubmed: 38375577
pmcid: 11380952
Jenkins RG, Moore BB, Chambers RC, Eickelberg O, Königshoff M, Kolb M, et al. An official American thoracic Society Workshop Report: Use of Animal models for the Preclinical Assessment of potential therapies for pulmonary fibrosis. Am J Respir Cell Mol Biol. 2017;56:667–79.
doi: 10.1165/rcmb.2017-0096ST
pubmed: 28459387
pmcid: 5800895
Caporarello N, Meridew JA, Jones DL, Tan Q, Haak AJ, Choi KM, et al. PGC1α repression in IPF fibroblasts drives a pathologic metabolic, secretory and fibrogenic state. Thorax. 2019;74:749–60.
doi: 10.1136/thoraxjnl-2019-213064
pubmed: 31182654
Weckerle J, Mayr CH, Fundel-Clemens K, Lämmle B, Boryn L, Thomas MJ, et al. Transcriptomic and proteomic changes driving Pulmonary Fibrosis Resolution in Young and Old mice. Am J Respir Cell Mol Biol. 2023;69:422–40.
doi: 10.1165/rcmb.2023-0012OC
pubmed: 37411041
Redente EF, Jacobsen KM, Solomon JJ, Lara AR, Faubel S, Keith RC, et al. Age and sex dimorphisms contribute to the severity of bleomycin-induced lung injury and fibrosis. Am J Physiol Lung Cell Mol Physiol. 2011;301:L510–8.
doi: 10.1152/ajplung.00122.2011
pubmed: 21743030
pmcid: 3191751
Sueblinvong V, Neujahr DC, Mills ST, Roser-Page S, Ritzenthaler JD, Guidot D, et al. Predisposition for disrepair in the aged lung. Am J Med Sci. 2012;344:41–51.
doi: 10.1097/MAJ.0b013e318234c132
pubmed: 22173045
pmcid: 3395069
Hecker L, Logsdon NJ, Kurundkar D, Kurundkar A, Bernard K, Hock T, et al. Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance. Sci Transl Med. 2014;6:231ra47.
doi: 10.1126/scitranslmed.3008182
pubmed: 24718857
pmcid: 4545252
Weckerle J, Picart-Armada S, Klee S, Bretschneider T, Luippold AH, Rist W, et al. Mapping the metabolomic and lipidomic changes in the bleomycin model of pulmonary fibrosis in young and aged mice. Dis Model Mech. 2022;15:dmm049105.
doi: 10.1242/dmm.049105
pubmed: 34845494
pmcid: 8807555
Klee S, Picart-Armada S, Wenger K, Birk G, Quast K, Veyel D, et al. Transcriptomic and proteomic profiling of young and old mice in the bleomycin model reveals high similarity. Am J Physiol Lung Cell Mol Physiol. 2023;324:L245–58.
doi: 10.1152/ajplung.00253.2021
pubmed: 36625483
Wollin L, Distler JHW, Redente EF, Riches DWH, Stowasser S, Schlenker-Herceg R, et al. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J. 2019;54:1900161.
doi: 10.1183/13993003.00161-2019
pubmed: 31285305
pmcid: 6751387
Kato K, Shin YJ, Palumbo S, Papageorgiou I, Hahn S, Irish JD, et al. Leveraging ageing models of pulmonary fibrosis: the efficacy of nintedanib in ageing. Eur Respir J. 2021;58:2100759.
doi: 10.1183/13993003.00759-2021
pubmed: 34531276
pmcid: 8613836
Huang K, Rabold R, Schofield B, Mitzner W, Tankersley CG. Age-dependent changes of airway and lung parenchyma in C57BL/6J mice. J Appl Physiol (1985). 2007;102:200–6.
doi: 10.1152/japplphysiol.00400.2006
pubmed: 16946023
Schulte H, Mühlfeld C, Brandenberger C. Age-related structural and functional changes in the mouse lung. Front Physiol. 2019;10:1466.
doi: 10.3389/fphys.2019.01466
pubmed: 31866873
pmcid: 6904284
Quirk JD, Sukstanskii AL, Woods JC, Lutey BA, Conradi MS, Gierada DS et al. Experimental evidence of age-related adaptive changes in human acinar airways. J Appl Physiol (1985). 2016; 120: 159–165.
Elliott JE, Mantilla CB, Pabelick CM, Roden AC, Sieck GC. Aging-related changes in respiratory system mechanics and morphometry in mice. Am J Physiol Lung Cell Mol Physiol. 2016;311:L167–76.
doi: 10.1152/ajplung.00232.2016
pubmed: 27288490
pmcid: 4967189
Veldhuizen RAW, McCaig LA, Pape C, Gill SE. The effects of aging and exercise on lung mechanics, surfactant and alveolar macrophages. Exp Lung Res. 2019;45:113–22.
doi: 10.1080/01902148.2019.1605633
pubmed: 31195852
Calyeca J, Balderas-Martínez YI, Selman M, Pardo A. Transcriptomic profile of the mice aging lung is associated with inflammation and apoptosis as important pathways. Aging. 2021;13:12378–94.
doi: 10.18632/aging.203039
pubmed: 33982668
pmcid: 8148450
Ruiz A, Flores-Gonzalez J, Buendia-Roldan I, Chavez-Galan L. Telomere Shortening and its Association with Cell Dysfunction in Lung diseases. Int J Mol Sci. 2021;23:425.
doi: 10.3390/ijms23010425
pubmed: 35008850
pmcid: 8745057
Mecozzi L, Mambrini M, Ruscitti F, Ferrini E, Ciccimarra R, Ravanetti F, et al. In-vivo lung fibrosis staging in a bleomycin-mouse model: a new micro-CT guided densitometric approach. Sci Rep. 2020;10:18735.
doi: 10.1038/s41598-020-71293-3
pubmed: 33127949
pmcid: 7603396
Vincenzi E, Fantazzini A, Basso C, Barla A, Odone F, Leo L, et al. A fully automated deep learning pipeline for micro-CT-imaging-based densitometry of lung fibrosis murine models. Respir Res. 2022;23:308.
doi: 10.1186/s12931-022-02236-x
pubmed: 36369209
pmcid: 9651107
Pennati F, Leo L, Ferrini E, Sverzellati N, Bernardi D, Stellari FF, et al. Micro-CT-derived ventilation biomarkers for the longitudinal assessment of pathology and response to therapy in a mouse model of lung fibrosis. Sci Rep. 2023;13:4462.
doi: 10.1038/s41598-023-30402-8
pubmed: 36932122
pmcid: 10023700
Buccardi M, Ferrini E, Pennati F, Vincenzi E, Ledda RE, Grandi A, et al. A fully automated micro–CT deep learning approach for precision preclinical investigation of lung fibrosis progression and response to therapy. Respir Res. 2023;24:126.
doi: 10.1186/s12931-023-02432-3
pubmed: 37161569
pmcid: 10170869
Ruscitti F, Ravanetti F, Bertani V, Ragionieri L, Mecozzi L, Sverzellati N, et al. Quantification of Lung Fibrosis in IPF-Like Mouse Model and pharmacological response to treatment by Micro-computed Tomography. Front Pharmacol. 2020;11:1117.
doi: 10.3389/fphar.2020.01117
pubmed: 32792953
pmcid: 7385278
Ferrini E, Mecozzi L, Corsi L, Ragionieri L, Donofrio G, Stellari FF. Alfaxalone and Dexmedetomidine as an alternative to gas anesthesia for Micro-CT lung imaging in a Bleomycin-Induced Pulmonary Fibrosis Murine Model. Front Vet Sci. 2020;7:588592.
doi: 10.3389/fvets.2020.588592
pubmed: 33134367
pmcid: 7578219
Mambrini M, Mecozzi L, Ferrini E, Leo L, Bernardi D, Grandi A, et al. The importance of routine quality control for reproducible pulmonary measurements by in vivo micro-CT. Sci Rep. 2022;12:9695.
doi: 10.1038/s41598-022-13477-7
pubmed: 35690601
pmcid: 9188608
Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol. 1988;41:467–70.
doi: 10.1136/jcp.41.4.467
pubmed: 3366935
pmcid: 1141479
Hübner RH, Gitter W, El Mokhtari NE, Mathiak M, Both M, Bolte H, et al. Standardized quantification of pulmonary fibrosis in histological samples. Biotechniques. 2008;44:507–17.
doi: 10.2144/000112729
pubmed: 18476815
Grandi A, Ferrini E, Mecozzi L, Ciccimarra R, Zoboli M, Leo L, et al. Indocyanine-enhanced mouse model of bleomycin-induced lung fibrosis with hallmarks of progressive emphysema. Am J Physiol Lung Cell Mol Physiol. 2023;324:L211–27.
doi: 10.1152/ajplung.00180.2022
pubmed: 36625471
pmcid: 9925167
Wadman M. FDA no longer has to require animal testing for new drugs. Science. 2023;379:127–8.
doi: 10.1126/science.adg6276
pubmed: 36634170
Khalajzeyqami Z, Grandi A, Ferrini E, Ravanetti F, Leo L, Mambrini M, et al. Pivotal role of micro-CT technology in setting up an optimized lung fibrosis mouse model for drug screening. PLoS ONE. 2022;17:e0270005.
doi: 10.1371/journal.pone.0270005
pubmed: 35704641
pmcid: 9200302
Wang F, Ting C, Riemondy KA, Douglas M, Foster K, Patel N, et al. Regulation of epithelial transitional states in murine and human pulmonary fibrosis. J Clin Investig. 2002;133:e165612.
doi: 10.1172/JCI165612
Yang Y, Wang X, Zhang J. Pirfenidone and Nintedanib attenuate pulmonary fibrosis in mice by inhibiting the expression of JAK2. J Thorac Disease. 2024;16:1128–40.
doi: 10.21037/jtd-23-1057
Komatsu M, Yamamoto H, Ichiyama T, Kawakami S, Uehara T, Yoshikawa Y, et al. Tolerability of nintedanib in the elderly with idiopathic pulmonary fibrosis: a single-center retrospective study. PLoS ONE. 2022;17:e0262795.
doi: 10.1371/journal.pone.0262795
pubmed: 35113907
pmcid: 8812933
Uchida Y, Ikeda S, Sekine A, Katano T, Tabata E, Oda T, et al. Tolerability and safety of nintedanib in elderly patients with idiopathic pulmonary fibrosis. Respir Investig. 2021;59:99–105.
doi: 10.1016/j.resinv.2020.08.003
pubmed: 32891571
Mondoni M, Alfano F, Varone F, Muscato G, Conti C, Saderi L, et al. Observational, Multicenter Study on the efficacy, tolerability, and Safety of Nintedanib in patients with idiopathic pulmonary fibrosis older than 80 years. Respiration. 2023;102:25–33.
doi: 10.1159/000527308
pubmed: 36366821
Buccardi M, Grandi A, Ferrini E, Buseghin D, Villetti G, Civelli M, et al. Micro-CT-assisted identification of the optimal time-window for antifibrotic treatment in a bleomycin mouse model of long-lasting pulmonary fibrosis. Sci Rep. 2024;14:14792.
doi: 10.1038/s41598-024-65030-3
pubmed: 38926490
pmcid: 11208517